Carol Berry

Carol Berry was appointed Chief Executive Officer of GMJ Technologies effective June 1, 2026, succeeding founder Tosin Dada, PhD, who remains as President and Chief Technology Officer. Berry brings over 30 years of experience in the life sciences and biotech industry. In her new role, she will oversee the company's long-term vision, goals, and strategic initiatives while managing funding strategies, partnerships, market expansion, and industry compliance for the Seattle-based developer of novel protein analysis technologies.

Berry's educational credentials include a Bachelor of Science from Texas A&M University and an M.B.A. in Information Technology Management from the University of Dallas. She has demonstrated deep expertise in diagnostics and personalized medicine, with more than 25 years of industry experience in personalized medicine and diagnostics.

Career History

• Senior Vice President and Chief Business Officer at Caprion Bioscience (now CellCarta), where she consistently delivered double digit revenue growth over nine years and positioned the company as a leader in the specialty contract research laboratory sector
• Senior Vice President and General Manager of the genomics services division at Asuragen, a molecular diagnostics company
• Board member at InterVenn Biosciences, a clinical technology company leveraging glycoproteomics
• Executive roles including Chief Business Officer for a specialized Clinical Research Organization and one of the top fifty General Managers at LabCorp

What Carol Berry could bring to CEO at GMJ Technologies: Berry's three-decade track record in life sciences commercialization, demonstrated revenue growth leadership at Caprion/CellCarta, and extensive experience navigating FDA regulatory pathways position her to accelerate GMJ Technologies' go-to-market strategy for its novel capillary electrophoresis technology. Her success scaling genomics and diagnostics businesses, combined with her board-level involvement in emerging biotech ventures, should enable her to drive partnerships, capital strategies, and market penetration in the proteomics and protein characterization space.